Abstract
Serum albumin is the most abundant protein in blood. It shows a variety of activities including antioxidant activities and binding activity toward lipophilic hormones, marker for glucose intolerance and protective effects. Albumin is used for the treatment of many diseases such as cancer, liver disease, renal disease, inflammatory disease, and cardiovascular infection. Over the last decade, various drug delivery systems have been created to improve the treatment of various disorders and diseases. Albumin has been generally studied as a protein carrier for the delivery of the drug. Especially, in nanotechnology, it is utilized for the delivery of various drug molecules for the sustained, control release and enhancement of bioavailability. So, the demand for albumin increased annually worldwide due to the different applications of albumin.
This chapter reviews recent progress in several key areas relevant to natural products in nano and micro delivery systems for biomedical applications and its production, purification, and distribution in the human body. Also the present chapter describes the special features of albumin as a drug carrier, and thereby provides scientists with knowledge of goal-driven design on albumin-based nanomedicine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ajaj AK, Graeser R, Fichtner I, Kratz F (2009) In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol 64:413–418. https://doi.org/10.1007/s00280-009-0942-8
Alderson P, Bunn F, Li Wan Po A, Li L, Pearson M, Roberts I, Schierhout G (2004) Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 4:310–319. https://doi.org/10.3748/wjg.v17.i30.3479
Arasteh A, Farahi S, Habibi-Rezaei M, Moosavi-Movahedi AA (2014) Glycated albumin: an overview of the in vitro models of an in vivo potential disease marker. J Diabetes Metab Disord 13:49–58. https://doi.org/10.1186/2251-6581-13-49
Bernardi M, Maggioli C, Zaccherini G (2012) Human albumin in the management of complications of liver cirrhosis. Crit Care 16:211–220. https://doi.org/10.1186/cc11218
Bertucci C, Domenici E (2002) Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem 9:1463–1481. https://doi.org/10.2174/0929867023369673
Blunt MC, Nicholson JP, Park JR (1998) Serum albumin and colloid osmotic pressure in survivors and non-survivors of prolonged critical illness. Anesthesia 53:755–761. https://doi.org/10.1046/j.1365-2044.1998.00488.x
Boussif O, Lezoualch O, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo. Proc Natl Acad Sci U S A 92:7297–7301. https://doi.org/10.1073/pnas.92.16.7297
Brzoska M, Langer K, Coester C, Loitsch S, Wagner TO, Mallinckrodt C (2004) Incorporation of biodegradable nanoparticles into human airway epithelium cells in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun 318:562–570. https://doi.org/10.1016/j.bbrc.2004.04.067
Buchacher A, Iberer G (2006) Purification of intravenous immunoglobulin g from human plasma aspects of yield and virus safety. Biotechnol J 1(2):148–163. https://doi.org/10.1002/biot.200500037
Chen R, Yue Z, Eccleston ME, Williams S, Slater NK (2005) Modulation of cell membrane disruption by pH-responsive pseudo-peptides through grafting with hydrophilic side chains. J Control Release 108:63–72. https://doi.org/10.1016/j.biomaterials.2008.12.036
Cho K, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–1316. https://doi.org/10.1158/1078-0432.CCR-07-1441
Curry S, Brick P, Franks NP (1999) Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim Biophys Acta 1441(2–3):131–140. https://doi.org/10.1016/s1388-1981(99)00148-1
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 41(2):580–637. https://doi.org/10.1097/CCM.0b013e31827e83af
Elena S, Claude N, Robert K, Andreas T, Ingrid PF, Christine V, Iris J, Massimo M (2012) Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 120(12):2405–2411. https://doi.org/10.1182/blood-2012-05-429688
Elsadek B, Kratz F (2012) Impact of albumin on drug delivery – new applications on the horizon. J Control Release 157:4–28. https://doi.org/10.1016/j.jconrel.2011.09.069
Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157(2):168–182. https://doi.org/10.1016/j.jconrel.2011.07.031
Evans TW (2002) Review article: albumin as a drug–biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 16:6–11. https://doi.org/10.1046/j.1365-2036.16.s5.2.x
Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P (2012) Human serum albumin: from bench to bedside. Mol Asp Med 33:209–290. https://doi.org/10.1016/j.mam.2011.12.002
Farrugia A (2011) Falsification or paradigm shift? Toward a revision of the common sense of transfusion. Transfusion 51(1):216–224. https://doi.org/10.1111/j.1537-2995.2010.02817.x
Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P (2005) The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57:787–796. https://doi.org/10.1080/15216540500404093
Faure P, Wiernsperger N, Polge C, Favier A, Halimi S (2008) Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci (Lond) 114:251–256. https://doi.org/10.1042/CS20070276
Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ (1999) Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 16:1576–1581. https://doi.org/10.1023/a:1018908705446
Fiume L, Di Stefano G, Busi C, Mattioli A, Bonino F, Torrani-Cerenzia M, Verme G, Rapicetta M, Bertini M, Gervasi GB (1997) Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J Viral Hepat 4:363–370. https://doi.org/10.1046/j.1365-2893.1997.00067.x
Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Treviño-Becerra A, Wanner C (2008) A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73(4):391–398. https://doi.org/10.1038/sj.ki.5002585
Garcia-Martinez R, Andreola F, Mehta G, Poulton K, Oria M, Jover M, Soeda J, Macnaughtan J, De Chiara F, Habtesion A, Mookerjee RP, Davies N, Jalan R (2015) The immunomodulatory and antioxidant function of albumin stabilizes the endothelium and improves survival in a rodent model of chronic liver failure. J Hepatol 62(4):799–806. https://doi.org/10.1016/j.jhep.2014.10.031
Gengoux C, Leclerc C (1995) In vivo induction of CD4 + T cell responses by antigen covalently linked to synthetic micro-spheres does not require adjuvant. Int Immunol 7:45–53. https://doi.org/10.1093/intimm/7.1.45
Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7:1041–1053. https://doi.org/10.1517/14656566.7.8.1041
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611–3619. https://doi.org/10.1200/JCO.2008.18.5397
Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ (2006) Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17(8):1263–1268. https://doi.org/10.1093/annonc/mdl104
Guevara M, Terra C, Nazar A, Solà E (2012) Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol 57:759–765. https://doi.org/10.1016/j.jhep.2012.06.013
Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69. https://doi.org/10.1186/1475-2891-9-69
Hauser CA, Stockler MR, Tattersall MH (2006) Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 14:999–1011. https://doi.org/10.1007/s00520-006-0079-9
Hirose M, Tachibana A, Tanabe T (2010) Recombinant human serum albumin hydrogel as a novel drug delivery vehicle. Mater Sci Eng C 30:664–669. https://doi.org/10.1016/j.msec.2010.02.020
Hu YJ, Liu Y, Sun TQ, Bai AM, Lü JQ, Pi ZB (2006) Binding of anti-inflammatory drug cromolyn sodium to bovine serum albumin. Int J Biol Macromol 39:280–285. https://doi.org/10.1016/j.ijbiomac.2006.04.004
Huang KS, Yang CH, Wang YC, Wang WT, Lu YY (2019) Microfluidic synthesis of vinblastine-loaded multifunctional particles for magnetically responsive controlled drug release. Pharmaceutics 11:1–14. https://doi.org/10.3390/pharmaceutics11050212
Irache JM, Merodio M, Arnedo A, Campanero MA, Mirshahi M, Espuelas S (2005) Albumin nanoparticles for the intravitreal delivery of anti-cytomegaloviral drugs. Mini-Rev Med Chem 5:293–305. https://doi.org/10.2174/1389557053175335
Julio R, Jane R, Mark B, Fred Y, Murray S (2009) Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32:1880–1886. https://doi.org/10.2337/dc09-0366
Kayani Z, Firuzi O, Bordbar AK (2018) Doughnut-shaped bovine serum albumin nanoparticles loaded with doxorubicin for overcoming multidrug-resistant in cancer cells. Int J Biol Macromol 107:1835–1843. https://doi.org/10.1016/j.ijbiomac.2017.10.041
Kazan A, Celiktas OY, Zhang YS (2019) Fabrication of thymoquinone loaded albumin nanoparticles by microfluidic particle synthesis and their effect on planarian regeneration. Macromol Biosci 14:182–192. https://doi.org/10.1002/mabi.201900182
Kersten G, Hirshberg H (2004) Antigen delivery systems. Expert Rev Vaccines 3:453–462. https://doi.org/10.1586/14760584.3.4.453
Kim SB, Chi HS, Park JS, Hong CD, Yang WS (1999) Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients. Am J Kidney Dis 33:312–317. https://doi.org/10.1016/s0272-6386(99)70306-9
Kragh-Hansen U (2013) Molecular and practical aspects of the enzymatic properties of human serum albumin and albumin-ligand complexes. Biochim Biophys Acta 1830(12):5535–5544. https://doi.org/10.1016/j.bbagen.2013.03.015
Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates, and nanoparticles. J Control Release 132:171–183. https://doi.org/10.1016/j.jconrel.2008.05.010
Kratz F (2014) A clinical update of using albumin as a drug vehicle a commentary. J Control Release 190:331–336. https://doi.org/10.1016/j.jconrel.2014.03.013
Kratz F, Beyer U, Roth T, Schu MT, Unold A, Fiebig HH, Unger C (1998) Albumin conjugates of the anticancer drug chlorambucil: synthesis, characterization, and in vitro efficacy. Arch Pharm Pharm Med Chem 331:47–53. https://doi.org/10.1002/(sici)1521-4184(199802)331:2<47::aid-ardp47>3.0.co;2-r
Lari RS, Moezi L, Pirsalami F, Abkar M, Moosavi M (2019) Curcumin-loaded BSA nanoparticles protect more efficiently than natural curcumin against scopolamine-induced memory retrieval deficit. Basic Clin Neurosci 10(2):157–164. https://doi.org/10.32598/bcn.9.10.255
Larsen ΜT, Kuhlmann M, Hvam ML, Howard KA (2016) Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther 4(1):1–13. https://doi.org/10.1186/s40591-016-0048-8
Lee E, Eom JE, Jeon KH, Kim TH, Kim E, Jhon GJ, Kwon Y (2014) Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. J Pharm Biomed Anal 91:17–23. https://doi.org/10.1016/j.jpba.2013.12.003
Li Q, Liu C, Zhao X, Zu Y, Wang Y, Zhang B, Zhao D, Zhao Q, Su L, Gao Y, Sun B (2011) Preparation, characterization and targeting of micronized 10-hydro-oxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells. Int J Nanomedicine 6:397–405. https://doi.org/10.2147/IJN.S16144
Li C, Zhang D, Guo H, Hao L, Zheng D, Liu G, Shen J, Tian X, Zhang Q (2013) Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin. Int J Pharm 448(1):79–86. https://doi.org/10.1016/j.ijpharm.2013.03.019
Lian B, Li Y, Zhao X, Zu Y, Wang Y, Zhang Y, Li Y (2017) Preparation and optimization of 10-hydro-oxy-camptothecin nano colloidal particles using the antisolvent method combined with high-pressure homogenization. J Chem 41:1–10. https://doi.org/10.1155/2017/5752090
Loureiro A, Azoia NG, Gomes AC, Cavaco-Paulo A (2016) Albumin-based nanodevices as drug carriers. Curr Pharm Des 22(10):1371–1390. https://doi.org/10.2174/1381612822666160125114900
Mendez CM, Mcclain CJ, Marsano LS (2005) Albumin therapy in clinical practice. Nutr Clin Pract 20:314–320. https://doi.org/10.1177/0115426505020003314
Murthy N, Xu M, Schuck S, Kunisawa J, Shastri N, Frechet MJ (2003) A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels. Proc Natl Acad Sci U S A 29:4995–5000. https://doi.org/10.1073/pnas.0930644100
Neumann E, Frei E, Funk D, Becker MD, Schrenk HH, Müller-Ladner U, Fiehn C (2010) Native albumin for targeted drug delivery. Expert Opin Drug Deliv 7:915–925. https://doi.org/10.1517/17425247.2010.498474
Nicholson JP, Wolmarans MR, Park GR (2000) The role of albumin in critical illness. Br J Anaesth 85(4):599–610. https://doi.org/10.1093/bja/85.4.599
O’Hagan DT (1998) Recent advances in immunological adjuvants: the development of particulate antigen delivery systems. Expert Opin Investig Drugs 7:349–359. https://doi.org/10.1517/13543784.7.3.349
Odunuga OO, Shazhko A (2013) Ammonium sulfate precipitation combined with liquid chromatography is sufficient for purification of bovine serum albumin that is suitable for most routine laboratory applications. Biochem Compounds 1(1):03–09. https://doi.org/10.7243/2052-9341-1-3
Onafuye H, Pieper S, Mulac D, Jr JC, Wass MN, Langer K, Michaelis M (2019) Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. Beilstein J Nanotechnol 10:1707–1715. https://doi.org/10.3762/bjnano.10.166
Patil GV (2003) Biopolymer albumin for diagnosis and in drug delivery. Drug Dev Res 58:219–247. https://doi.org/10.1002/ddr.10157
Plank C, Zauner W, Wagner E (1998) Application of membrane-active peptides for drug and gene delivery across cellular membranes. Adv Drug Deliv Rev 34:21–35. https://doi.org/10.1016/s0169-409x(98)00005-2
Poca M, Concepción M, Casas M, Alvarez-Urturi C, Gordillo J, Hernández-Gea V, Román E, Guarner-Argente C, Gich I, Soriano G, Guarner C (2012) Role of albumin treatment in patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 10:309–315. https://doi.org/10.1016/j.cgh.2011.11.012
Ramesh N, Mandal AK (2019) Encapsulation of epigallocatechin-3-gallate into albumin nanoparticles improves pharmacokinetic and bioavailability in rat model. Biotech 9(6):238–246. https://doi.org/10.1007/s13205-019-1772-y
Ramin R, Ali M, Neda K, Fatemeh S, Sara S, Jalal A (2016) Overview of albumin and its purification methods. Adv Pharm Bull 6(4):495–507. https://doi.org/10.15171/apb.2016.063
Raoufinia R, Mota A, Keyhanvar N, Safari F, Shamekhi S, Abdolalizadeh J (2016a) Overview of albumin and its purification methods. Adv Pharm Bull 6(4):495–507. https://doi.org/10.15171/apb.2016.063
Raoufinia R, Mota A, Nozari S, Aghebati Maleki L, Balkani S, Abdolalizadeh J (2016b) A methodological approach for purification and characterization of human serum albumin. J Immunoass Immunochem 37(6):623–635. https://doi.org/10.1080/15321819.2016.1184163
Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008) The antioxidant properties of serum albumin. FEBS Lett 582(13):1783–1787. https://doi.org/10.1016/j.febslet.2008.04.057
Roco MC (2003) Nanotechnology: convergence with modern biology and medicine. Curr Opin Biotechnol 14:337–346. https://doi.org/10.1016/s0958-1669(03)00068-5
Russell JA, Navickis RJ, Wilkes MM (2004) Albumin versus crystal- crystalloid for pump-priming in cardiac surgery: a meta-analysis of controlled trials. J Cardiothorac Vasc Anesth 18:429–437. https://doi.org/10.1053/j.jvca.2004.05.019
Saleh T, Saudi T, Shojaosadati SA (2019) Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells. Int J Biol Macromol 1(130):109–116. https://doi.org/10.1016/j.ijbiomac.2019.02.129
Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S (2010) Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomedicine 5:525–532. https://doi.org/10.2147/ijn.s10443
Shai Y (1995) Mechanism of the binding, insertion, and destabilization of phospholipid bilayer membranes by a-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1462:55–70. https://doi.org/10.1016/s0005-2736(99)00200-x
Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ (2006) Enhanced and prolonged cross-presentation following the endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117:78–88. https://doi.org/10.1111/j.1365-2567.2005.02268.x
Simoes S, Slepushkin V, Pires P, Gaspar R, de Lima RMC, Duzgunes N (2004) Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum. Biochim Biophys Acta 1463:459–469. https://doi.org/10.1016/s0005-2736(99)00238-2
Sleep D (2015) Albumin and its application in drug delivery. Expert Opin Drug Deliv 12(5):793–812. https://doi.org/10.1517/17425247.2015.993313
Sleep D, Cameron J, Evans LR (2013) Albumin is a versatile platform for drug half-life extension. Biochim Biophys Acta 1830:5526–5534. https://doi.org/10.1016/j.bbagen.2013.04.023
Sokołowska M, Wszelaka-Rylik M, Poznański J, Bal W (2009) Spectroscopic and thermodynamic determination of three distinct binding sites for Co(II) ions in human serum albumin. J Inorg Biochem 103:1005–1013. https://doi.org/10.1016/j.jinorgbio.2009.04.011
Standley SM, Kwon TJ, Murthy N, Kunisawa J, Shastri N, Guillaudeu SJ, Lau L, Fréchet JMJ (2004) Acid-degradable particles for protein-based vaccines: enhanced survival rate for tumor-challenged mice using ovalbumin model. Bioconjug Chem 15:1281–1288. https://doi.org/10.1021/mp800068x
Storni T, Kundig TM, Senti G, Johansen P (2005) Immunity in response to particulate antigen delivery systems. Adv Drug Deliv Rev 57:333–355. https://doi.org/10.1016/j.addr.2004.09.008
Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 1:02–16. https://doi.org/10.1186/1745-6673-2-16
Taghdisi SM, Danesh NM, Ramezani M, Abnous K (2016) Targeted delivery of vincristine to T-cell acute lymphoblastic leukemia cells using an aptamer-modified albumin conjugate. RSC Adv 6(52):46366–46371. https://doi.org/10.1039/C6RA08481H
Tanaka K, Shigueoka EM, Sawatani E, Dias GA, Arashiro F, Campos TC, Nakao HC (1998) Purification of human albumin by the combination of the method of Cohn with liquid chromatography. Braz J Med Biol Res 31(11):1383–1388. https://doi.org/10.1590/s0100-879x1998001100003
Taneja N, Singh KK (2018) Rational design of polysorbate 80 stabilized human serum albumin nanoparticles tailored for high drug loading and entrapment of irinotecan. Int J Pharm 536(1):82–94. https://doi.org/10.1016/j.ijpharm.2017.11.024
Tantra R, Tompkins J, Quincey P (2010) Characterisation of the de-agglomeration effects of bovine serum albumin on nanoparticles in aqueous suspension. Colloids Surf B: Biointerfaces 75:275–281. https://doi.org/10.1016/j.colsurfb.2009.08.049
Tao C, Chuah YJ, Xu CJ, Wang DA (2019) Albumin conjugates and assemblies as versatile bio-functional additives and carriers for biomedical applications. J Mater Chem B 7:357–367. https://doi.org/10.1039/C8TB02477D
Taverna M, Marie AL, Mira JP, Guidet B (2013) Specific antioxidant properties of human serum albumin. Ann Intensive Care 3(1):04–11. https://doi.org/10.1186/2110-5820-3-4
Tazhbayev Y, Mukashev M, Burkeev M, Kreuter J (2019) Hydroxyurea-loaded albumin nanoparticles: preparation, characterization, and in vitro studies. Pharmaceutics 11(8):410–422. https://doi.org/10.3390/pharmaceutics11080410
Tuncay M (2000) In vitro and in vivo evaluation of diclofenac sodium loaded albumin microspheres. J Microencapsul 17(2):145–155. https://doi.org/10.1080/026520400288382
Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G (2010) Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J 159:570–576. https://doi.org/10.1016/j.ahj.2009.12.026
Varshney A, Sen P, Ahmad E, Rehan M, Subbarao N, Khan RH (2010) Ligand binding strategies of human serum albumin: how can the cargo be utilized? Chirality 22(1):77–87. https://doi.org/10.1002/chir.20709
Wang W, Ou Y, Shi Y (2004) AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 21:2105–2111. https://doi.org/10.1023/b:pham.0000048203.30568.81
Weber C, Coester C, Kreuter J, Langer K (2000) Desolvation process and surface characteristics of protein nanoparticles. Int J Pharm 194:91–102. https://doi.org/10.1016/s0378-5173(99)00370-1
Wongsasulak S, Patapeejumruswong M, Weiss J, Supaphol P, Yoovidhya T (2010) Electrospinning of food-grade nanofibers from cellulose acetate and egg albumin blends. J Food Eng 98:370–376. https://doi.org/10.1016/j.jfoodeng.2010.01.014
Yessine MA, Leroux JC (2004) Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of bio-macromolecules. Adv Drug Deliv Rev 56:999–1021. https://doi.org/10.1016/j.addr.2003.10.039
Zhou T, Lu S, Liu X, Zhang Y, Xu F (2013) Review of the rational use and adverse reactions to human serum albumin in the people’s Republic of China. Patient Prefer Adherence 7:1207–1212. https://doi.org/10.2147/PPA.S53484
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Dewangan, H.K. (2020). Albumin as Natural Versatile Drug Carrier for Various Diseases Treatment. In: Saneja, A., Panda, A., Lichtfouse, E. (eds) Sustainable Agriculture Reviews 43. Sustainable Agriculture Reviews, vol 43. Springer, Cham. https://doi.org/10.1007/978-3-030-41838-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-41838-0_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-41837-3
Online ISBN: 978-3-030-41838-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)